Skip to content
Screener

Cronos Group CRON Reportable Segment — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Bicara Therapeutics logo
BCAXReportable Segment — R&D
$47.5M+38.4%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%

Other financials

Income statement

See full
Revenue$53.0M+58.4%
Gross profit$28.5M+96.2%
Operating income$7.4M+239%
Net income$32.1M+181%
EPS (diluted)$0.09+190%

Balance sheet

See full
Cash & equivalents$467.0M-41.2%
Total debt$1.3M-35.6%
Total equity$1.1B-1.3%
Total assets$1.2B+0.4%

Cash flow

See full
Operating cash flow$24.0M+752%
CapEx$1.7M-54.7%
Free cash flow$22.3M+2,286%

Valuation

See full
Market cap$1.14B+11.7%
Enterprise value$676.36M+194%
P/E16.3×-39.0×
P/S6.4×-1.5×

Profitability

See full
Gross margin45.9%+13.1pp
Operating margin-1.4%-0.7pp
Net margin39.1%+24.9pp
FCF margin27.8%+23.2pp

Returns & leverage

See full
Return on equity6.5%+4.8pp
Debt / equity0.0×
Current ratio16.2×-8.5×

Where this comes from

Reported directly by Cronos Group in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Cronos Group’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001656472-26-000051
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Inventory write-down388861,05386
Significant operating expenses:
Sales and marketing6,7855,34712,4009,912
Research and development1,2159292,6281,722
General and administrative, excluding transaction costs10,22210,50420,99919,773
Share-based compensation1,5571,3812,8703,469
Depreciation and amortization3798678041,363
Total significant operating expenses20,15819,02839,70136,239

Item 1. Financial Statements.

FAQ

What is Cronos Group's reportable segment — R&D?
Cronos Group (CRON) reported reportable segment — R&D of $1.22M in Q2 2026.
How has Cronos Group's reportable segment — R&D changed year-over-year?
Cronos Group's reportable segment — R&D increased by 30.8% year-over-year, from $929K to $1.22M.
What is the long-term trend for Cronos Group's reportable segment — R&D?
Over 3 years (2022 to 2025), Cronos Group's reportable segment — R&D has grown at a -30.3% compound annual growth rate (CAGR), from $13.13M to $4.45M.
What does reportable segment — R&D mean?
This metric measures the expenditures dedicated to innovation, product development, and scientific research within the reportable segment. It highlights the company's commitment to long-term growth through the creation of new offerings or the improvement of existing product formulations.

Ask your AI about Cronos Group's reportable segment — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude